New Delhi [India], September 1 (ANI: India's first indigenously developed quadrivalent Human Papilloma Virus (qHPV) vaccine will be available at an affordable price, said Serum Institute of India (SII) CEO Adar Poonawala on Thursday.
New Delhi [India], August 31 (ANI): The Serum Institute of India (SII) and the Department of Biotechnology(DBT) are set to launch India's first indigenously developed Quadrivalent Human Papillomavirus vaccine (qHPV) against Cervical Cancer on September 1, official sources told ANI.
Pune (Maharashtra) [India], August 17 (ANI): Highlighting 75 years of the US-India bilateral relationship and their cooperation on health issues, a US delegation visited the Serum Institute of India (SII) in Pune today and noted the critical role played by US-India cooperation in addressing
New Delhi [India], July 12 (ANI): India's first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer gets Drugs Controller General of India (DCGI) approval for market authorisation. This vaccine will be manufactured by the Serum Institute of India (SII).
New Delhi [India], June 28 (ANI): The Drugs Controller General of India (DCGI) has given restricted emergency use authorisation (EUA) to Pune-based Serum Institute of India's COVID-19 vaccine 'Covovax' for children aged 7 to 12 years, sources told ANI.
New Delhi [India], June 15 (ANI): The subject expert committee meeting that was scheduled today to discuss Serum Institute of India's (SII) indigenously developed Quadrivalent human papillomavirus (qHPV) vaccine against cervical cancer, has recommended regular market authorisation for above
New Delhi [India] June 15 (ANI): The first indigenously developed quadrivalent human papillomavirus (qHPV) vaccine against cervical cancer by the Serum Institute of India (SII) will be discussed by the Subject expert committee on Wednesday.
Pune (Maharashtra) [India], May 5 (ANI): Chief Executive Officer of Pune based Serum Institute of India Adar Poonawalla on Wednesday clarified that the COVID-19 vaccine Covovax is available for everyone above the age of 12 years.
New Delhi [India], May 3 (ANI): Serum Institute of India (SII) CEO Adar Poonawalla on Tuesday said that the COVID-19 vaccine Covovax is now available in India for children.
New Delhi [India], April 30 (ANI): The Drugs Controller General of India's (DCGI) subject expert committee on Friday sought more data from Pune based Serum Institute of India (SII) on the Covovax vaccine for the age group of 7-12 years.
New Delhi [India], April 29 (ANI): National Technical Advisory Group on Immunisation (NTAGI) on Friday approved Serum Institute of India's Covovax COVID-19 vaccine for the age group 12-17, said sources.
New Delhi [India], April 22 (ANI): British Prime Minister Boris Johnson on Friday highlighted the collaboration between Oxford-Astra Zeneca and the Serum Institute of India (SII) for the production of COVID-19 vaccines and emphasised that he has "the Indian jab" in his arms.